Sarcoidosis is a systemic, noncaseating granulomatous disease with an unknown etiology which is known to affect many organs. The liver is one of the most frequently affected. In many cases, hepatic involvement can be subtle. The present case is presented to emphasize that granulomatous foci detected in a biopsy performed to determine the reason for high levels of liver enzymes may play a guiding role in the determination of etiology.

Case Report {#sec1-2}
===========

In 2010, a 53-year-old female patient was consulted to the gastroenterology clinic with complaints of fatigue and abdominal pain. Biochemical analysis revealed elevated blood levels of alanine aminotransferase (41 U/L), aspartate aminotransferase (108 U/L), alkaline phosphatase (ALP; 649 U/L), gamma-glutamyltransferase (GGT; 361 U/L) and a negative autoimmune panel. Ultrasound examination revealed hepatomegaly, and thoracic computed tomography results indicated that the lymph nodes in the mediastinum, paratracheal, and precarinal regions were 2x1 cm in size. Tru-Cut biopsy (Becton Dickenson and Co., Franklin Lakes, NJ, USA) of the liver was performed with the initial diagnoses of tuberculosis, lymphoma, and sarcoidosis. The histopathological evaluation indicated noncaseating granulomatous inflammation in the parenchyma consistent with grade 3 macrovesicular steatosis and foci of intralobular non-necrotising granulomatous inflammation ([Figs. 1](#F1){ref-type="fig"}-[3](#F3){ref-type="fig"}). Ziehl-Neelsen staining results were unremarkable. As the angiotensin-converting enzyme level was 5 times higher than the upper limit of normal (250 U/L; normal: 8-52 U/L), the case was evaluated as sarcoidosis with hepatic involvement, and the patient was sent to a center with a sarcoidosis polyclinic. Treatment and follow-up continue.
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Discussion {#sec1-3}
==========

Sarcoidosis is a disease with an unknown etiology characterized by granulomatous inflammation which most frequently affects the lungs, followed by the lymphoid system. In more than 90% of cases it is characterized by the presence of noncaseating granulomas containing activated T lymphocytes and mononuclear phagocytic cells in the lungs and lymph nodes, and may include the skin and eyes.\[[@ref1], [@ref2]\] The most affected intraabdominal organs are the liver, spleen, and lymph nodes. The liver is the third most frequently involved organ.\[[@ref1]\] The most frequent sign of hepatic involvement in sarcoidosis is hepatomegaly, seen in more than half of the cases. Multiple nodules formed by the aggregation of granulomas may be observed in the liver.\[[@ref3]\]

Most cases with hepatic involvement have a subtle clinical course. In some cases, jaundice, chronic cholestasis, portal hypertension, and Budd-Chiari syndrome may develop.\[[@ref4], [@ref5]\] Cirrhosis is a very rarely seen entity in less than 1% of cases\[[@ref6], [@ref7]\] Granulomas are the characteristic histological feature in sarcoidosis.\[[@ref6]\] In liver biopsies, granulomas have been reported in 60% to 80% of patients with sarcoidosis. However, laboratory findings of palpable hepatomegaly and/or liver involvement are detected in only 20% to 30% of the patients. Rarely, hepatic involvement might be the only manifestation of the disease. Sarcoidosis frequently affects the periportal areas. Isolated granulomatous hepatitis may be seen. If active hepatic inflammation is present, fever and upper left quadrant tenderness may be observed. In hepatic sarcoidosis, frequently, abnormalities in liver function tests are detected. The level of transaminases and bilirubin are slightly increased, and typically the values are greater than those of ALP and GGT transaminases. A cholestatic pattern may be seen.\[[@ref8]\] In hepatic sarcoidosis, granulomatous lesions are often very small and clinically asymptomatic. Asymptomatic hepatic involvement and slightly increased transaminases do not require treatment; however, in cases with a marked increase in transaminases or severe hepatic dysfunction, steroids are used. With treatment, the levels of enzymes normalize. If chronic granulomatous inflammation in the liver cannot be prevented, progressive hepatic cirrhosis, intrahepatic cholestasis, and portal hypertension may develop.\[[@ref8]\] Frequently, intrahepatic cholestasis is seen in biopsy material. Cholestasis may develop as a consequence of cholestasis, hepatic granulomas, sarcoidotic involvement of intra- or extrahepatic biliary ducts, or compression of the common biliary duct by enlarged perihilar lymph nodes.\[[@ref9], [@ref10]\] Cholestasis was not observed in our case. In addition to foci of granulomatous inflammation, Grade 3 macrovesicular steatosis was present. The relationship between sarcoidosis and hepatosteatosis is not known. However, microgranulomas may accompany hepatosteatosis. Both of these conditions may lead to increased hepatic enzyme levels. Many diseases may induce formation of granulomas. These include autoimmune diseases (sarcoidosis, primary biliary cirrhosis, Wegener's granulomatosis, Crohn's disease), bacterial infections (mainly tuberculosis); viral infections (cytomegalovirus, Epstein-Barr virus infections, hepatitis A,B,C infections) fungal infections (histoplasmosis, cryptococcosis), parasitoses (toxoplasmosis, schistosomiasis), malignancies (especially Hodgkin's lymphoma), medications, and idiopathic causes of disease.\[[@ref11], [@ref12]\] When establishing a diagnosis, other clinical and laboratory findings of the patients in addition to histopathological characteristics are also important. The follow-up and treatment of this patient with a final diagnosis of sarcoidosis still continues.
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